Definium Therapeutics, Inc.

DFTX

NASDAQHealthcareBiotechnology

Open in GoAI

Latest quote

$44.89

−$0.49 · -1.08%

Aug 21, 3:55 PM ET

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

41/100

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

Expensive

Momentum

Gaining

Sentiment

Mixed

Risk resilience

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.

Industry: Biotechnology
Sector: Healthcare
Headquarters: US
CEO: Robert Barrow
Listed since: Nov 15, 2016
Employees: 106